In an attempt to optimize praziquantel use for the treatment of schistosomiasis, the WHO Special Programme for Research and Training in Tropical Diseases (TDR) launched in 2003 a series of multi-country trials, comparing the efficacy and safety of 40 mg/kg and 60 mg/kg in schistosome-infected patients in Asia, Africa, and the Americas.